Galapagos NV (NASDAQ:GLPG) Short Interest Update

Galapagos NV (NASDAQ:GLPG) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 1,500,000 shares, an increase of 5.6% from the March 31st total of 1,420,000 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average daily volume of 124,300 shares, the days-to-cover ratio is presently 12.1 days.

Wall Street Analysts Forecast Growth

GLPG has been the subject of a number of recent research reports. StockNews.com lowered shares of Galapagos from a “buy” rating to a “hold” rating in a report on Monday, March 18th. Morgan Stanley reissued an “equal weight” rating and issued a $38.00 target price on shares of Galapagos in a report on Monday, April 22nd. Finally, Bank of America reissued an “underperform” rating and issued a $31.00 target price (down from $41.00) on shares of Galapagos in a report on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $34.50.

Institutional Trading of Galapagos

Several institutional investors and hedge funds have recently made changes to their positions in GLPG. GAMMA Investing LLC bought a new stake in shares of Galapagos during the fourth quarter worth $44,000. Quadrant Capital Group LLC lifted its position in shares of Galapagos by 18.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 261 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Galapagos by 2,317.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,934 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 1,854 shares during the last quarter. Signaturefd LLC lifted its position in shares of Galapagos by 78.6% during the fourth quarter. Signaturefd LLC now owns 1,970 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 867 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Galapagos by 357.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,265 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 1,770 shares during the last quarter. 32.46% of the stock is currently owned by institutional investors.

Galapagos Stock Up 0.4 %

NASDAQ GLPG opened at $29.45 on Friday. The company has a fifty day moving average of $32.25 and a two-hundred day moving average of $36.04. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -12.86 and a beta of 0.27. Galapagos has a 52 week low of $28.30 and a 52 week high of $45.21.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.